 | • レポートコード：MRC2312MG09042 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、79ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の抗VEGT薬市場規模と予測を収録しています。・世界の抗VEGT薬市場：売上、2018年-2023年、2024年-2029年 ・世界の抗VEGT薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の抗VEGT薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「チロシンキナーゼ阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 抗VEGT薬のグローバル主要企業は、Genentech (Roche)、 Regeneron Pharmaceuticals、 Novartis、 AstraZeneca、 Bayer、 Abbott、 Santen、 Pfizer、 Sanofi、 Bristol-Myers Squibb、 GlaxoSmithKline、 Eli Lilly & Company、 Chugai Pharma、 Kanghong Pharmaceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、抗VEGT薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の抗VEGT薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の抗VEGT薬市場：タイプ別市場シェア、2022年 ・チロシンキナーゼ阻害剤、モノクローナル抗体、その他 世界の抗VEGT薬市場：用途別、2018年-2023年、2024年-2029年 世界の抗VEGT薬市場：用途別市場シェア、2022年 ・腫瘍、眼科、その他 世界の抗VEGT薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の抗VEGT薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における抗VEGT薬のグローバル売上、2018年-2023年 ・主要企業における抗VEGT薬のグローバル売上シェア、2022年 ・主要企業における抗VEGT薬のグローバル販売量、2018年-2023年 ・主要企業における抗VEGT薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Genentech (Roche)、 Regeneron Pharmaceuticals、 Novartis、 AstraZeneca、 Bayer、 Abbott、 Santen、 Pfizer、 Sanofi、 Bristol-Myers Squibb、 GlaxoSmithKline、 Eli Lilly & Company、 Chugai Pharma、 Kanghong Pharmaceutical ************************************************************* ・調査・分析レポートの概要 抗VEGT薬市場の定義 市場セグメント 世界の抗VEGT薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の抗VEGT薬市場規模 世界の抗VEGT薬市場規模：2022年 VS 2029年 世界の抗VEGT薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの抗VEGT薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の抗VEGT薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：チロシンキナーゼ阻害剤、モノクローナル抗体、その他 抗VEGT薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：腫瘍、眼科、その他 抗VEGT薬の用途別グローバル売上・予測 ・地域別市場分析 地域別抗VEGT薬市場規模 2022年と2029年 地域別抗VEGT薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Genentech (Roche)、 Regeneron Pharmaceuticals、 Novartis、 AstraZeneca、 Bayer、 Abbott、 Santen、 Pfizer、 Sanofi、 Bristol-Myers Squibb、 GlaxoSmithKline、 Eli Lilly & Company、 Chugai Pharma、 Kanghong Pharmaceutical ... |
This research report provides a comprehensive analysis of the Anti-VEGT Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Anti-VEGT Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Anti-VEGT Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Anti-VEGT Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Anti-VEGT Drugs market presents opportunities for various stakeholders, including Oncology, Ophthalmology. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Anti-VEGT Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Anti-VEGT Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Anti-VEGT Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Anti-VEGT Drugs market.
Market Overview: The report provides a comprehensive overview of the Anti-VEGT Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Tyrosine Kinase Inhibitors, Monoclonal Antibodies), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Anti-VEGT Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Anti-VEGT Drugs market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Anti-VEGT Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Anti-VEGT Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Anti-VEGT Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Anti-VEGT Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Anti-VEGT Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Anti-VEGT Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Anti-VEGT Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
Others
Market segment by Application
Oncology
Ophthalmology
Others
Global Anti-VEGT Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Genentech (Roche)
Regeneron Pharmaceuticals
Novartis
AstraZeneca
Bayer
Abbott
Santen
Pfizer
Sanofi
Bristol-Myers Squibb
GlaxoSmithKline
Eli Lilly & Company
Chugai Pharma
Kanghong Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-VEGT Drugs, market overview.
Chapter 2: Global Anti-VEGT Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Anti-VEGT Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-VEGT Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Anti-VEGT Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Anti-VEGT Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Anti-VEGT Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Anti-VEGT Drugs Overall Market Size
2.1 Global Anti-VEGT Drugs Market Size: 2022 VS 2029
2.2 Global Anti-VEGT Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Anti-VEGT Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Anti-VEGT Drugs Players in Global Market
3.2 Top Global Anti-VEGT Drugs Companies Ranked by Revenue
3.3 Global Anti-VEGT Drugs Revenue by Companies
3.4 Global Anti-VEGT Drugs Sales by Companies
3.5 Global Anti-VEGT Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Anti-VEGT Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Anti-VEGT Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Anti-VEGT Drugs Players in Global Market
3.8.1 List of Global Tier 1 Anti-VEGT Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Anti-VEGT Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Anti-VEGT Drugs Market Size Markets, 2022 & 2029
4.1.2 Tyrosine Kinase Inhibitors
4.1.3 Monoclonal Antibodies
4.1.4 Others
4.2 By Type – Global Anti-VEGT Drugs Revenue & Forecasts
4.2.1 By Type – Global Anti-VEGT Drugs Revenue, 2018-2023
4.2.2 By Type – Global Anti-VEGT Drugs Revenue, 2024-2029
4.2.3 By Type – Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Anti-VEGT Drugs Sales & Forecasts
4.3.1 By Type – Global Anti-VEGT Drugs Sales, 2018-2023
4.3.2 By Type – Global Anti-VEGT Drugs Sales, 2024-2029
4.3.3 By Type – Global Anti-VEGT Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Anti-VEGT Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Anti-VEGT Drugs Market Size, 2022 & 2029
5.1.2 Oncology
5.1.3 Ophthalmology
5.1.4 Others
5.2 By Application – Global Anti-VEGT Drugs Revenue & Forecasts
5.2.1 By Application – Global Anti-VEGT Drugs Revenue, 2018-2023
5.2.2 By Application – Global Anti-VEGT Drugs Revenue, 2024-2029
5.2.3 By Application – Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Anti-VEGT Drugs Sales & Forecasts
5.3.1 By Application – Global Anti-VEGT Drugs Sales, 2018-2023
5.3.2 By Application – Global Anti-VEGT Drugs Sales, 2024-2029
5.3.3 By Application – Global Anti-VEGT Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Anti-VEGT Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Anti-VEGT Drugs Market Size, 2022 & 2029
6.2 By Region – Global Anti-VEGT Drugs Revenue & Forecasts
6.2.1 By Region – Global Anti-VEGT Drugs Revenue, 2018-2023
6.2.2 By Region – Global Anti-VEGT Drugs Revenue, 2024-2029
6.2.3 By Region – Global Anti-VEGT Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Anti-VEGT Drugs Sales & Forecasts
6.3.1 By Region – Global Anti-VEGT Drugs Sales, 2018-2023
6.3.2 By Region – Global Anti-VEGT Drugs Sales, 2024-2029
6.3.3 By Region – Global Anti-VEGT Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Anti-VEGT Drugs Revenue, 2018-2029
6.4.2 By Country – North America Anti-VEGT Drugs Sales, 2018-2029
6.4.3 US Anti-VEGT Drugs Market Size, 2018-2029
6.4.4 Canada Anti-VEGT Drugs Market Size, 2018-2029
6.4.5 Mexico Anti-VEGT Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Anti-VEGT Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Anti-VEGT Drugs Sales, 2018-2029
6.5.3 Germany Anti-VEGT Drugs Market Size, 2018-2029
6.5.4 France Anti-VEGT Drugs Market Size, 2018-2029
6.5.5 U.K. Anti-VEGT Drugs Market Size, 2018-2029
6.5.6 Italy Anti-VEGT Drugs Market Size, 2018-2029
6.5.7 Russia Anti-VEGT Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Anti-VEGT Drugs Market Size, 2018-2029
6.5.9 Benelux Anti-VEGT Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Anti-VEGT Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Anti-VEGT Drugs Sales, 2018-2029
6.6.3 China Anti-VEGT Drugs Market Size, 2018-2029
6.6.4 Japan Anti-VEGT Drugs Market Size, 2018-2029
6.6.5 South Korea Anti-VEGT Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Anti-VEGT Drugs Market Size, 2018-2029
6.6.7 India Anti-VEGT Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Anti-VEGT Drugs Revenue, 2018-2029
6.7.2 By Country – South America Anti-VEGT Drugs Sales, 2018-2029
6.7.3 Brazil Anti-VEGT Drugs Market Size, 2018-2029
6.7.4 Argentina Anti-VEGT Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Anti-VEGT Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Anti-VEGT Drugs Sales, 2018-2029
6.8.3 Turkey Anti-VEGT Drugs Market Size, 2018-2029
6.8.4 Israel Anti-VEGT Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Anti-VEGT Drugs Market Size, 2018-2029
6.8.6 UAE Anti-VEGT Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Genentech (Roche)
7.1.1 Genentech (Roche) Company Summary
7.1.2 Genentech (Roche) Business Overview
7.1.3 Genentech (Roche) Anti-VEGT Drugs Major Product Offerings
7.1.4 Genentech (Roche) Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Genentech (Roche) Key News & Latest Developments
7.2 Regeneron Pharmaceuticals
7.2.1 Regeneron Pharmaceuticals Company Summary
7.2.2 Regeneron Pharmaceuticals Business Overview
7.2.3 Regeneron Pharmaceuticals Anti-VEGT Drugs Major Product Offerings
7.2.4 Regeneron Pharmaceuticals Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Regeneron Pharmaceuticals Key News & Latest Developments
7.3 Novartis
7.3.1 Novartis Company Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Anti-VEGT Drugs Major Product Offerings
7.3.4 Novartis Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Novartis Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Anti-VEGT Drugs Major Product Offerings
7.4.4 AstraZeneca Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 Bayer
7.5.1 Bayer Company Summary
7.5.2 Bayer Business Overview
7.5.3 Bayer Anti-VEGT Drugs Major Product Offerings
7.5.4 Bayer Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Bayer Key News & Latest Developments
7.6 Abbott
7.6.1 Abbott Company Summary
7.6.2 Abbott Business Overview
7.6.3 Abbott Anti-VEGT Drugs Major Product Offerings
7.6.4 Abbott Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.6.5 Abbott Key News & Latest Developments
7.7 Santen
7.7.1 Santen Company Summary
7.7.2 Santen Business Overview
7.7.3 Santen Anti-VEGT Drugs Major Product Offerings
7.7.4 Santen Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Santen Key News & Latest Developments
7.8 Pfizer
7.8.1 Pfizer Company Summary
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Anti-VEGT Drugs Major Product Offerings
7.8.4 Pfizer Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Pfizer Key News & Latest Developments
7.9 Sanofi
7.9.1 Sanofi Company Summary
7.9.2 Sanofi Business Overview
7.9.3 Sanofi Anti-VEGT Drugs Major Product Offerings
7.9.4 Sanofi Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.9.5 Sanofi Key News & Latest Developments
7.10 Bristol-Myers Squibb
7.10.1 Bristol-Myers Squibb Company Summary
7.10.2 Bristol-Myers Squibb Business Overview
7.10.3 Bristol-Myers Squibb Anti-VEGT Drugs Major Product Offerings
7.10.4 Bristol-Myers Squibb Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Bristol-Myers Squibb Key News & Latest Developments
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Company Summary
7.11.2 GlaxoSmithKline Business Overview
7.11.3 GlaxoSmithKline Anti-VEGT Drugs Major Product Offerings
7.11.4 GlaxoSmithKline Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.11.5 GlaxoSmithKline Key News & Latest Developments
7.12 Eli Lilly & Company
7.12.1 Eli Lilly & Company Company Summary
7.12.2 Eli Lilly & Company Business Overview
7.12.3 Eli Lilly & Company Anti-VEGT Drugs Major Product Offerings
7.12.4 Eli Lilly & Company Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.12.5 Eli Lilly & Company Key News & Latest Developments
7.13 Chugai Pharma
7.13.1 Chugai Pharma Company Summary
7.13.2 Chugai Pharma Business Overview
7.13.3 Chugai Pharma Anti-VEGT Drugs Major Product Offerings
7.13.4 Chugai Pharma Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.13.5 Chugai Pharma Key News & Latest Developments
7.14 Kanghong Pharmaceutical
7.14.1 Kanghong Pharmaceutical Company Summary
7.14.2 Kanghong Pharmaceutical Business Overview
7.14.3 Kanghong Pharmaceutical Anti-VEGT Drugs Major Product Offerings
7.14.4 Kanghong Pharmaceutical Anti-VEGT Drugs Sales and Revenue in Global (2018-2023)
7.14.5 Kanghong Pharmaceutical Key News & Latest Developments
8 Global Anti-VEGT Drugs Production Capacity, Analysis
8.1 Global Anti-VEGT Drugs Production Capacity, 2018-2029
8.2 Anti-VEGT Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Anti-VEGT Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Anti-VEGT Drugs Supply Chain Analysis
10.1 Anti-VEGT Drugs Industry Value Chain
10.2 Anti-VEGT Drugs Upstream Market
10.3 Anti-VEGT Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Anti-VEGT Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
